To determine by sequential coronary arteriography whether a lipid-lowering diet with and
without lipid-lowering drugs could reverse coronary artery disease in normocholesterolemic
patients. Also, to test whether fish oil supplements could improve human coronary
atherosclerosis. Finally, to determine the effect of combination therapy with lipid-reducing
drugs in patients with coronary heart disease and "normal" cholesterol levels. At least three
clinical trials were conducted.
To determine the relative effectiveness of moderate versus more aggressive lipid lowering,
and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass
graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous
vein coronary bypass grafts placed 1 to 11 years previously.
Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1973-06-01
To determine whether reduction of cholesterol by drug therapy significantly lowered the
atherosclerotic coronary heart disease rate in a group of hypercholesterolemic but otherwise
healthy men.
Total dollars spent on the CPPT from June 1973 were $142,250,000. We do not have a
year-by-year breakdown.
To determine whether lowering of cholesterol with cholestyramine in a population with Type II
hyperlipidemia led to a decreased rate of progression (a regression of coronary artery
disease) as demonstrated by death, myocardial infarction, or progression of disease on
angiography.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
